Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) covers the month of November 2002. The report focuses on the announcement of results from the CREDO (Clopidogrel for Reduction of Events During Observation) clinical study, presented at the American Heart Association Scientific Sessions on November 18, 2002. The study evaluates the long-term efficacy of clopidogrel (Plavix/Iscover) in combination with aspirin for patients undergoing percutaneous coronary intervention (PCI).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period. The document is a clinical study announcement rather than a financial earnings report.
Material Changes and Clinical Results
The primary material update is the positive outcome of the CREDO study, which involved 2,116 patients across 99 centers in the U.S. and Canada. Key findings include:
- Risk Reduction: Long-term (one year) treatment with clopidogrel and aspirin resulted in a statistically significant 27% reduction in the relative risk of death, heart attack, or stroke compared to aspirin alone (p=0.02).
- Event Rates: The combined endpoint occurred in 8.5% of the clopidogrel group versus 11.5% in the placebo group.
- Loading Dose Efficacy: Patients receiving a loading dose at least six hours prior to PCI showed a 39% relative risk reduction in death, heart attack, or urgent target vessel revascularization at 28 days.
- Safety Profile: There was no statistically significant increase in bleeding compared to aspirin alone, though a trend toward increased major bleeding was observed (8.8% vs 6.7%). No fatal bleeds or intracranial hemorrhages were reported.
Outlook, Guidance, and Management Commentary
Management and study investigators highlighted the following:
- Guideline Alignment: The results support recent updates to treatment guidelines by the ACC/AHA and ESC, which recommend long-term antiplatelet therapy for PCI patients.
- Market Impact: With approximately 850,000 PCI procedures performed annually in the U.S., the data may encourage broader physician adoption of the guidelines.
- Future Pipeline: Clopidogrel is undergoing a massive international development program involving over 80,000 patients across cardiology, neurology, and other vascular indications (studies include COMMIT, CLARITY, MATCH, CHARISMA, ACTIVE, CASPAR, and CAMPER).
- Commercial Reach: To date, more than 15 million patients worldwide have been treated with clopidogrel.
Investor Verification Checklist
- Verify the commercial impact of the CREDO study results on Plavix sales volumes and market share in the coming quarters.
- Monitor regulatory updates regarding the approval of new indications based on the ongoing 80,000-patient clinical development program.
- Review the safety data regarding the trend in major bleeding rates (8.8% vs 6.7%) and its potential impact on prescribing patterns.
- Confirm the status of the co-development and marketing agreement with Bristol-Myers Squibb for Plavix and irbesartan.
- Assess the competitive landscape for antiplatelet therapies in the PCI and acute coronary syndrome markets.